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Summary m-L-sarcolysin (m-L-SL) is an isomer of melphalan (Mel) with the di(2-chloroethyl) amino group being substituted in the meta
position of phenylalanine. By covalent conjugation of amino acids to m-L-SL. a peptide complex consisting of six m-L-SL-based oligopeptides
known as peptichemio (PTC) was developed previously. In the present study, the cytotoxic activity pattem of the different oligopeptides of
PTC was investigated in ten human tumour cell lines representing different mechanisms of cytotoxic drug resistance using the fluorometric
microcufture cytotoxicity assay (FMCA). In the cell line panel, L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine (P2) was the most active
oligopeptide, showing slightly lower mean IC5 values (2.6 vs 3.9 and 4.1 usg ml'M) than Mel and m-L-SL. The otherfive oligopeptides were less
active than Mel. All active oligopeptides showed mechanistic similarity to Mel as judged by the correlation analysis of the cell line panel
log IC5 values (R > 0.90). although P2 appeared to be less sensitive to GSH-mediated drug resistance. The relative activity of Mel and P2
was found to be related to degree of proliferation. P2 being more active towards low-proliferating cell lines. P2 and Mel were then further
characterized in 49 fresh human tumour samples. In these samples P2 was considerably more active than Mel and showed a higher relative
solid tumour activity (2.7 to 4.5-fold). However, the correlation of log IC s between P2 and Mel in patient cells was high (R = 0.79). indicating
a similar mechanism of action in this tumour model too. Cross-resistance with other standard drugs was lower for P2 than Mel. The results
show that P2 is the most potent component of PTC and demonstrates a favourable activity profile compared with Mel. These data suggest
that further investigation of P2 as a potential anti-tumour agent is warranted.
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m-L-sarcolx sin (m-L-SL ) is an isomer ofmelphalan (Mel) wxith the
di(2-chloroethv1) amino group being substituted in the meta posi-
tion of phenx lalanine. Bv cox-alent conju2ation of different aniino
acids at the amino and carboxxl groups of m-L-SL. a peptide
complex including six oligopeptides knoxx-n as peptichemio
(PTC) \vas svnthesized prexiouslx (De Barbieri. 1972). The main
rationale for svnthesizing, PFC wias that of creatin2 a substance
that is simultaneouslx endowed w-ith cxtotoxic actix-itv because of
the alkx lating group and a selecti-xe uptake in neoplastic cells (De
Barbieri. 1972). In sexeral clinical inxestigations. PTC has showin
actixitx in a Aiide spectrum of human malignancies (Hug et al.
1980: Paccagnella et al. 1985. 1986). In the clinic PTC has showin
acti-it- in human multiple myeloma resistant to treatment wxith
alkvlating agents IPaccagnella et al. 1986: Zaniboni et al. 1988).
Increased cx-totoxicitx- exerted by PTC as compared w-ith Mel and
m-L-SL has been showin on tumour cell lines (Lewxensohn et al.
1991a). One of the alkylating peptides in PTC is L-prolyl-m-L-
sarcol\s -l-L-p-fluorophenx lalamnne (P21. We haxe previously
found that P2 is sex-eral-fold more toxic to human melanoma cells
than m-L-SL alone w-hen tested bv a clono2enic assav (Hansson et
al. 19911. Increased levels of DNA cross-link-in2 w-ere noted after
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exposure to P2 as compared wxith m-L-SL lHansson et al. 1991). In
the present paper we investigated the cytotoxic actixity of the
components of PTC in a panel of tumour cell lines representing
defined mechanisms of resistance. In addition. the most active
oligopeptide. P2. w-as further studied in prnmar- cultures ofhuman
tumour cells from patients.
MATERIALS AND METHODS
Cell lines
To evaluate the actixvitv patterns of P2 and M,el a human cell line
panel of four sensitixve parental cell lines. fi e drug resistant
sublines. representing different mechanisms ofresistance. and one
cell line w-ith primary resistance wxas used. The cell lines included
x ere the mveloma cell line RPMII 8226/S and its sublines
8226/Dox; and 8226/LR-5 (kind gifts from W'S Dalton.
Department of Medicine. Arizona Cancer Center. University of
Arizona. Tucson. AZ. USA). the lymphoma cell lines U-937-GTB
and U-937-Vcr (kind Lifts from K Nilsson. Department of
Pathologv. Unixersitv of Uppsala. Sweden). the small-cell lung
cancer (SCLC) cell line NCI-H69 and its subline H69AR
(American Ty-pe Culture Collection: ATCC. Rockvxille. MD.
USA). the renal adenocarcinoma cell line ACHN (ATCC ) and the
leukaemic cell line CCRF-CEMI and its subline CE.N/VMI-1 (kind
gifts from WAT Beck. Department of Pharmacologx. College of
Mledicine. Unixersitv ofTennessee. Memphis. TN. USA).
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The 8'26/Dox, x was selected for doxorubicin resistance and
shows the classical MDR phenotype with oxverexpression of P-
glxcoprotein 170 (Dalton et al. 1986). The 82"6/LR-5 w-as selected
for NMel resistance. proposed to be associated w-ith increased lexels
of glutathione (Bellamr et al. 1991: Mulcahv et al. 1994). The
t-937-Vcr was selected for -incristine resistance. proposed to be
tubulin associated (Botling et al. 1994). The H69AR. selected for
doxorubicin resistance. expresses a multidruc-resistant (MDR
phenotype proposed to be mediated by a multidrug resistance-
associated protein (MRP Mirski et al. 1987: Cole et al. 1992). The
CENIVM-1. selected for teniposide resistance. expresses an
atypical MDR. which is proposed to be topoisomerase LI (topoll)
associated (Danks et al. 1987. 1988). The exact mechanism of
resistance for the primary resistant ACHN cell line is not know-n
and may be multifactorial (Nv-gren and Larsson. 1990).
The cell lines w ere grow-n in complete culture medium
described belowx at 37^C in humidified atmosphere containing 5%'
carbon dioxide. The 8226/Dox, vk-as treated once a month w-ith
doxorubicin at 0.24 igc ml-' and the 8226/LR-5 at each change of
medium w-ith Mel at 1.53 .gg ml-. The U-937-Vcr was continu-
ously cultured in the presence of 10 ng ml-' vincristine and the
H69AR >-as alternately fed w-ith drug-free medium and medium
containincg 0.46 zg ml-' doxorubicin. The CEMI/VM-1 cell line
was cultured in drug-free medium without anv loss of resistance
for a period of 6-8 months. The resistance patterns ofthe cell lines
were routinely confirmed in control experiments.
Patient samples
A total of49 patient tumour samples from the different dia2nostic
group w-as used to determine the actixitx of P2. MIel. and. for
comparison. fix-e other cytotoxic drugs w-ere chosen to represent
different mechanistic classes. Hoxxever. because of a limited
number of cells. all drugs could not be tested in all samples.
Tw-entv-eiaht solid and 21 haematological tumours w-ere used to
determine the dose-response relationship for P2 and Mel. The
diagnostic groups of oriain w-ere: acute lyvmphocytic leukaemia
(seven). acute myelocytic leukaemia (eight). chronic lymphocytic
leukaemia (four). myeloma (twxo). carcinoma ofthe bladder (one).
breast cancer (four). non-small-cell lung cancer (six). oxarian
carcinoma (eight). phaeochromocytomra (one). sarcoma )tu-o).
carcinoma of the thy roid ( one). mesothelioma ( one). unknow-n
primarx (one). gastric cancer (one). cardiac carcinoma (one).
neuroblastoma (one). The oxerall percentage of prexviously
untreated patients w-as 58c%. Fix-e samples of normal peripheral
blood mononuclear cells (PBMCs) from healthy blood donors
were compared w ith those of the fi e chronic lymphocytic
leukaemia CLL) samples.
The tumour samples were obtained by bone marrow-/peripheral
blood sampling. routine surgerv or diagnostic biopsy. and this
samplincg was approved by the local ethics committee at the
Uppsala Unixversity Hospital. Leukaemic cells and PB.MCs w-ere
isolated from bone marrowx or peripheral blood by 1.077 g ml-
Ficoll-Paque (Kabi-Pharmacia. Uppsala. Svveden) densitx
gradient centrifugation (Larsson et al. 1992). Tumour tissue from
solid tumour samples was minced into small pieces and tumour
cells w-ere then isolated by collagenase dispersion followed by
Percoll (Kabi-Pharmacia) densit-v aradient centrifuciation (Csoka
et al. 1994). Cell xiabilitv wxas determined by the trypan blue
exclusion test and the proportion of tumour cells in the preparation
>-as judged by inspection of Iax-Grrinxx-ald-Ciemsa-stained
Table 1 Chemical composition of peptichemio oligopeptides
Peptide 1 (P1): L-Ser-LpFPhe-L-mSL.OEt
Peptide 2 (P2): L-Pro-L-mSL-LpFPhe.OEt
Peptide 3 (P3): L-pFPhe-L-mSL-Asn.OEt
Peptide 4 (P4):L-mSL-L-Arg(N02)-L-Nval.OEt
Peptide 5 (P5): L-pFPhe-Gty-L-mSL-L-Nval.OEt
Peptide 6 (P6). L-mSL-L-Arg-L-Lys-L-mSL-L-His.OMe
cytospin preparations by a cytopathologist. In some cases. cells
xwere cryopreserxed in a culture medium containing 10I
dimethylsulphoxide (DMSO: Sigma Chemical Co.. St Louis. MIO.
USA) and 50%;- inactivated fetal calf serum (FCS: HvClone.
Cramlington. UK) by initial freezing for 24 h at -70-C. followed
by storage in hquid nitrogen or in the deep freeze at -150C.
Cryopreserxation in this w-ax does not affect drug sensitix ity
(N-gren et al. 1992).
Reagents and drugs
Fluorescein diacetate (FDA: Sigma) was dissolxed in DMSO and
kept frozen (-20-C) as a stock solution protected from liaht. A
complete medium consistine of culture medium RPMI-1640
(Hy Clone. Cramlington. UK) supplemented w-ith 10% inactix-ated
FCS. 2 nmI glutamine. 50 .tg ml-' streptomwcin and 60 !gL ml-'
penicillin xxas used throuthout for both cell lines and patient
samples. Mel x-as obtained from the Wellcome Foundation.
London. UK. The drug was receixed as a sterile powxder. 2 mg of
wxhich wxere dissolxed in 0.5-1 ml of 92% ethanol xwith 2%
hydrogen chloride and further diluted in cell culture medium
to the desired drug concentrations. The components of PTC and
m-L-m-L-SL _ere obtained from Istituto Sieroterapico. Milanese.
S. Belfanti. Milan. Italy. The peptides 1-5 wxere obtained as ethyl
esters and peptide 6 as methyl ester (Table 1). An aliquot of 2 mg
of each >-as dissolxed in 0.5-1 ml of 92% ethanol wxith
hvdrochloric acid and further diluted in cell culture medium to the
desired drug concentrations. Cisplatin. cvtarabine. doxorubicin.
etoposide andx incristine xxere obtained from commercial sources
and wxere dissolxved accordin2 to cuidelines from the manufac-
turer and further diluted in phosphate-buffered saline (PBS:
HvClone) or sterile wxater.
In the cell line panel all drugs xxere tested at four different drug
concentrations. obtained by fixvefold serial dilution from the
maximum 10 [ag ml-'. On a molar basis the concentration of the
different oligopetides are 39-43% of that of Mel and m-L-SL. To
determine the dose-response relationship for Mel and P2 in patient
samples. fi e different drug concentrations x ere used. obtained bx
a fixefold serial dilution of the drugs from 50 jg ml-l. In the
patient samples. the concentrations chosen for comparison wxith
standard drugs xxere the empirically derixed cut-offconcentrations
EDCCs). defined as the concentration that produces a significant
scatter of sun-ixal index (SI) -alues among haematological
tumours. This concentration wxas used to optimize the conditions
for exaluating cross-resistance. The concentrations 2 and
0.08 jg ml-' xere chosen for Mel and P2. respectixely. and the
EDCCs for the other drugs hax-e been described prexviously
)Larsson et al. 1992).
Ninety-six-wxell microtitre plates (Nunc. Roskilde. Denmark)
x ere prepared wxith 20gl perwxell ofdrug solution at ten times the
desired concentration. with the aid of a programmable pipetting
robot (Propette. Perkin Elmer. Norwxalk. CT. USA). The plates
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were stored frozen at -70°C for up to 2 months until further use.
Under these conditions. no apparent change in drug activity was
observed (Larsson et al. 1992).
The fluorometric microculture cytotoxicity assay
procedure
The fluorometfic microculture cytotoxicity assay (FMCA) is
based on measurement of fluorescence generated from hydrolysis
of FDA to fluorescein by cells with intact plasma membranes and
has been described in detail previously (Larsson et al. 1992).
Briefly. the cells were resuspended in complete medium. and
180 jl of cell suspension was seeded into the wells of 96-well
experimental microtitre plates prepared with drugs as described.
Cell densities were 5-20 x 10- cells per well for the cell lines.
10-20 x 103 cells per well for the solid tumour cells and 50-
100 x 103 cells per well for the haematological tumour cells. Each
drug and concentration was tested in triplicate. Six wells with cells
but without drugs served as control and six wells with only culture
medium as blank.
The plates were incubated for 72 h at 37°C in humidified condi-
tions containing 5% carbon dioxide. At the end of the incubation
period the plates were centrifuged (200g, 5 min) and the medium
was removed by aspiration. After one wash in PBS. 100gl per
well of FDA dissolved in PBS (10 jg ml-') was added. The plates
were incubated for 45 min and the generated fluorescence (excita-
tion 480 nm) from each well was measured at 538 nm in a 96well
scanning fluorometer (Fluoroscan II. Labsystems Oy, Helsinki.
Finland). The fluorescence is proportional to the number of intact
cells in the well.
To evaluate the schedule dependency of drug activity. CCRF-
CEM cells and ACHN cells were used and were exposed to the
drug for 2. 4 or 72 h followed by washing with PBS, addition of
new culture medium and analysis at 72 h. Stability of P2 and Mel
under assay conditions was investigated by a bioassay. Plates
prepared with Mel and P2 were preincubated with 100 Rl medium
per well fordifferent time periods. ranging from 0 to 72 h. at 37°C
before cell suspension (U-937-GTB) was added. The activity of
the drugs after different preincubation times was evaluated by
comparing the SI values obtained after a further 72 h incubation
with FMCA. as described above.
Quality control
Quality criteria for a successful analysis included a fluorescence
signal in the control wells of more than five times mean blank
value. a mean coefficient ofvariation (CV) in the control wells of
less than 30% and more than 70% tumor cells in the cell prepara-
tion before incubation.
Quantification of FMCA results
Cell survival is presented as survival index (SI). defined as the
fluorescence in experimental wells in per cent of that in control
wells. with blank values subtracted. The IC., was defined as the
concentration giving a SI of50%.
For both cell lines and primary cultures. the ICsos were evalu-
ated for each individual cell line and drug with custom-made
computer software (Dharet al. 1996). A delta value was calculated
as the logarithm of the IC5O of the individual cell line minus the
mean of all ten log IC<os (Fridborg et al. 1996). The resistance
factors (RFs) in each subline were defined as the IC., ofthe resis-
tant subline divided by the IC., of its sensitive parental cell line.
The pairs ofparental/resistant cell lines used for RFcalculations of
P-glycoprotein (P-gp). MRP. topo II. glutathione (GSH) and
tubulin-associated resistance were RPMI 8226S/8226Dox40. NCI-
H69/H69AR. CCRF-CEM/CEM-VM-1. RPMI 8226S/8226LR-5
and U-937-GTB/U-937-Vcr respectively. Correlation coefficients
were determined using Pearson's correlation coefficient. Response
rate was defined as the fraction ofsamples having a SI below 50%
at 0.5 jg ml-' for all samples investigated. In vitro therapeutic
index was calculated as median IC., ofCLL samples/median IC.,
ofnormal PBMCs.
Measurement of DNA synthesis
In some experiments bromodeoxyuridine (BrdU) incorporation
into cellular DNA was determined with an enzyme-linked
immunosorbent assay (ELISA) kit from Boehringer Mannheim
(Mannheim, Germany) essentially according to the protocol
provided by the manufacturer. Briefly. cells were incubated in
96-well plates for 72 h in the presence of BrdU. The cells were
then fixed and an antibody directed to BrdU was added. The
formed immune complex was detected by a substrate reaction
using tetramethylbenzidine and measured in a spectrophotometric
microplate reader (Dynatech. Billingshurst. UK).
RESULTS
Activity pattems of PTC oligopeptides in the cell line
panel resembles that of Mel
Concentration-response curves for Mel in the cell line panel are
shown in Figure IA. Delta. the deviation oflogICS, from the mean
log IC,, of the cell line panel. is shown in Figure IB. When the
patterns of deltas for Mel were compared with those of m-L-SL
and the components ofPTC using Pearson's correlation analysis. a
high correlation was obtained for several of the m-L-SL oligo-
peptides (Table 2). For m-L-SL. P1. P2 and P4 the correlation
coefficients were > 0.90. No correlation was established with
P6 as an IC,O was reached in only one cell line.
P2 is more potent than the other PTC oligopeptides
P2 was the most active m-L-SL oligopeptide. which showed
a slightly lower mean IC5, (2.6jg ml-') compared with Mel
(3.9jg ml-') and m-L-SL (4.1 jg ml-'). However, on a molar basis.
the IC5, value for P2 was 3.3 times lower than m-L-SL. P1 showed
an IC5o of4.1 jg ml-' whereas the remaining m-L-SL oligopeptides
had IC_ s between 5.8 and 9.1 (Table 2). P2 was the only oligopep-
tide producing a SI below 50% in all the tested cell lines (Table 2).
P2 appears not to be affected by GSH-associated
resistance
Although. the overall activity profile resembled that of Mel. P2
appeared not to be affected by GSH-associated resistance as deter-
mined by the low resistance factor obtained using the LR5-parental
IC< ratio (RF 1.05. Table 3). Mel and m-L-SL, on the other hand.
showed RFs of 3.1 and 3.8 respectively. P2 also appeared less
sensitive to MRP-associated resistance than Mel and m-L-SL with
RFs of 1.55. 4.0 and 4.17 respectively (Table 3). Neither of the
drugs was affected by the remaining resistance mechanisms.
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Table 2 Results of comparative testing of Mel (melphalan) and the related
compounds in a mechanism-based cell line panel.-
Rank Drug ICwa Rt IC , IC50
mean max min
1 Mel 3.9 1.0 10 0.29
2 m-L-SL 4.1 0.99 9.1 0.61
3 P1 4.1 0.97 10 1.1
4 P4 6.8 0.92 10 1.8
5 P2 2.6 0.90 5.3 0.38
6 P5 5.8 0.81 10 1.5
7 P3 7.6 0.69 10 1.6
8 P6 9.1 nd 10 1.2
-For the ten cell lines depicted in Figure 1 mean IC5s were determined for all
oligopepbdes and the results are expressed as ug mV4. -Correlations of the
cell line panel log IC c values using Mel as the reference compound.
B
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Figure 1 Effect of Mel on survival index (SI) for all investigated cell lines.
Survival index: fluorescence in test wells/fluorescence in control wells with
blank values subtracted (A). From these concentration-response curves.
mean log,, IC5. was determined defined as the mean of the log,, values of all
ten individual IC5cs obtained for the drug. Then, the difference between the
log,, of each cell line and the mean log,: IC5c was calculated to yield a
variable defined as delta (x-axis). A mean graph consisting of the drug-
specific deltas across the cell line panel could then be constructed to
visualize differenbal cytotoxicity pattems of drugs (B). Thus. bars projectng to
the left (negative values) indicate cell lines more sensitive than the average
and bars projectng to the right (positive values) indicate drugs more resistant
than the average for a particular drug. See also Materials and methods
P2 is more active than Mel against primary human
tumour cells from patients
The actix itv of P2 and Mel was then further charactenrzed in 49
fresh human tumour samples. 21 from haematological and 28 from
solid tumour patients. In these samples P2 w as considerably more
actixve than Mel. shoxx ing IC., xalues of 0.51 and 8.6 compared
w-ith 2.3 and 23.8 PLg ml-' for haematological and solid tumour
samples respectixvelv (Figure 2). 'When compared %%-ith the cell
lines. P2 %x as significantlx more actixve against the primary
cultures. showina an ICN ratio for Mel oxer P2 of 11.2 compared
w-ith 1.5 for the cell lines. A tendencx towxards hiaher relatix e solid
tumour actixvit-v for P2 w as also obser-xed. tx-o and six solid tumour
samples showing negatire deltas compared with oxerall mean
xvalue for P2 and Mel respectixvelv (Figrure 2).
The six solid tumour samples were from patients Awith oxvarian
cancer (two). neuroblastoma. non-small-cell lung! cancer. breast
cancer and carcinoid tumour. At clinicallx achie'vable exposure for
Table 3 Resistance factors for Mel (melphalan). m-L-SL (Sarcolysine) and
P2
Resistance factors (RF)a
Resistance mechanism Mel m-L-SL P2
P-gp-associated MDR 0.99 0.95 0.96
Topo Il-associated MDR 0.52 0.76 0.69
Tubulin-associated MDR 0.75 0.96 1.02
GSH-associated MDR 3.10 3.80 1.05
MRP-associated MDR 4.0 4.17 1.55
aResistance factor (RF) = IC5 in resistant cell line/lC5 in parental cell line.
Results are presented as one typical experiment out of three.
Mel (2.0g.l ml- ) an in xitro response rate (percentage of samples
x-ith > 50%7- decrease in SI) of 67-i and 0%`7 x-as observed for
haematological and solid tumour samples respectix ely. The corre-
sponding response rates for P2 wvas 100%;- and 43%e (Table 4).
P2 is more active than Mel on low-proliferating tumour
cell systems
To investioate whetherthe increased actixvitx ofP2 could be related
to the lowx proliferatixe rate of the primarv cultures. the ratio of
Mel vs P2 IC__s in the cell lines >-as plotted against the rate of
proliferation under assay conditions in V-shaped plates (Figure 3 .
An inxerse relationship w-as observed (R = 0.70). P2 beina more
actixe against the low--proliferating cell lines. The next series of
experiments aimed to determine w-hether this relationship w-as
causall1 related to proliferation rather than being cell-type
specific. ACHN. w-hich shows a lowx grow-th rate in V-shaped
plates but proliferates rapidlv when seeded into flat-bottomed
plates. was used for this purpose. VWhen tested in flat-bottomed
plates P2. Mel and m-L-SL showed similar IC.,s (not shown). In
V-shaped plates. on the other hand. the corresponding IC for Mel
and m-L-SL w-as significantlv increased (four- to fixvefold).
w-hereas. by comparison P2 retained much of its actixitv (< twxo
fold. not shown). Stabilitx- under assav conditions determined bv a
bioassax was similar for Mlel and P2 (half-life of approximatelv
2 h. not shown) and 2-. 4- and 72-h exposure times showed similar
relatixe concentration-response relationships for the two drugs
(not showxn).
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Fgjure 2 From concentration-response curves of Mel (A) and P2 (B)
obtained from 49 primary human tumour cell samples (21 haematokogical and
28 solid tumour samples), mean Iog,O IC,, was determined defined as the
mean of the Ilog, values of all 49 indIvidual IC,,s obtained for the drug. Then,
the dlerence between the bg,O of each tumour cell sample and the mean
log,0IC., was calcuated to yield a variable defined as delta (x-axis). A mean
graph consing of the drug-specific deltas across the cell line panel could
ten be constructed to visulize differential cytotoxity pattems of drugs (B).
Thus, bars projectng to Fte left (negative values) incicate tumour samples
more senstive than the average and bars prjecting to the nght (positve
values) indicate drugs more resstant Ftan the average for a partcular drug.
See also Materiafis and methods
P2 shows a low degree of cross-resistance to standard
agents
Not only in the cell line panel (Table 2) but also in the primary
cultures (Figure 4). was the correlation between P2 and Mel rela-
tively high, indicating a similar mode of action. However, cross-
resistance to standard drugs determined using the haematological
Table 4 In vitro acvity of Mel and P2 on pnrnary cultures of human tumour
cells from patients with haematobgical and solid tumours.
KCs (sd.) R o rate (%)
Tumour type P2 Mel P2 Mel n
Haematobogical tumours 0.51 (0.52) 2.3 (2.6) 100 67 21
Solid tumours 8.6 (13.4) 23.8 (18.8) 43 0 28
Total 5.2 (10.9) 14.6 (17.8) 67 28 49
aResponse rate was defined as the number ofsamples with>50%/O decrease
in SUtotal number of samples x 100 at 2 ggml-, for each drug.
samples was generally low (0.14-0.43. Table 5). The correlation
with doxorubicin. etoposide and cisplatin was much lower for P2
than Mel. whereas the correlations with cytarabine and vincristine
were of similar magnitude (Table 5)
P2 shows a similar in vitrotherapeutic index to Mel in
low-prolifeaing cell systems
P2 also showed lower IC 0s than Mel in PBMCs with median
values of 0.27 and 4.0 respectively (n = 5). However. when
compared with medianIC-,values ofmalignant CLL samples. 0.07
and 1.4 gg ml-' respectively (n = 5) the in vitro therapeutic index
(IC_,PBMCs/IC_0 CLL) was 3.9 for P2 and 2.8 for Mel (Table 6).
DISCUSSION
Mel and m-L-SL are closely related aromatic nitrogen mustard
derivatives. The two molecules differonly in theposition ofthe di-
(2-chloroethyl) amino-group, which is in the para position in Mel
and in the meta position in m-L-SL. By conjugation of additional
amino acids to the carboxyl and amino groups of m-L-SL. a
complex consisting of six different peptides has been developed.
This mixture of peptides. PTC. has shown clinical activity in
several human malignancies (Hug et al, 1980; Paccagnella et al.
1986; Zaniboni et al, 1988). In previous investigations with the
human melanoma cell line RPMI 8322. PTC as well as some ofits
individual peptides were more effective than Mel and m-L-SL
(Lewensohn et al, 1991a: Hansson et al. 1991). Myeloma cells
isolated from bone marrow of patients with primary myelomas
were more sensitive to PTC than to Mel (Paccagnella et al, 1985).
In the human melanoma cell line RPMI 8322, used in the above-
mentioned investigation, we found that one ofthe peptides in PTC.
L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine (P2), showed a
higher toxicity than free m-L-SL as measured by the clonogenic
assay (Hansson et al, 1991).
In the present study we show that P2 was the most active
component of PTC when tested in a panel of human tumour cell
lines. Moreover, P2 was also more active than Mel and m-L-SL
against several of the cell lines. Correlation analysis of cell line
panel activity pattems demonstrated a close relationship between
P2 and Mel, suggesting a similar mode ofaction. However. unlike
Mel and m-L-SL, P2 appeared not to be affected by GSH- and
MRP-associated resistance to any greater extent. We have previ-
ously found, using a clonogenic assay, that buthionine sulphox-
imine, which depletes GSH, sensitizes a melanoma cell line to Mel
but to a lesser extent to P2 (Hansson et al, 1991). The previous
results with BSO as well as the present. showing low RFs for
GSH-mediated resistance, may indicate less dependence on
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Figure 3 Relationship between MeUP2 IC- ratios and number of doubling
times 72 h- determined by haemocytometer counts in the cell line panel
(n = 10). R = Pearson's correlation coefficent
Table 5 Correlation of Mel and P2 with standard drugs in haematological
tumour cell samples from patients at EDCC
Compound Mel (R)a P P2(R) P n
Doxorubicin 0.63 <0.01 0.32 NS 20
Vincristine 0.36 NS: 0.43 NS 20
Etoposide 0.45 NS 0.14 NS 19
Cytarabine 0.39 NS 0.37 NS 20
Cisplatin 0.58 <0.05 0.24 NS 14
-Pearson's correlation coefficient. -NS. not significant (P > 0.05).
Table 6 Comparison of median IC cs in CLL and normal PBMC samples for
P2 and Mel
Celltype lcso P2 C50 Mel
PBMC (n = 5) 0.27 4.0
CLL (n = 5) 0.07 1.4
Ratio PBMC/CLH 3.9 2.8
PBMC. peripheral blood mononuclear cell: CLL. chronic fymphocytic
leukaemia.
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In contrast to proliferating cell lines. human tumour biopsy cells
R 9 were as a group significantly more sensitix-e to the cxtotoxic
* activitx of P2 than Mel. The reason for this mav be related to the
loxw proliferatix-e activitx of the primarx cultures in the present
assax system (Weisenthal et al. 1991W as low-proliferating cell
lines also showed higher relatix-e P2 sensitivitv. Furthermnore.
direct manipulation of the proliferative rate of the ACHN cell line
produced the correspondinc alterations of Mel vs P2 sensitivitt-.
From a clinical point of view. the demonstrated abilitv of P2 to
retain activity against non-cycling cells may be a distinct advan-
taae as the lox- grow-th fraction of manv solid tumours is a limiting
* factor for therapeutic responses of most currently used antineo-
plastic arents. The indications of a wider spectrum of anti-tumour
X r l activity and a favourable therapeutic index in vitro as ",ell as the
-1.5 -1 -0.5 0 0.5 1 1.5 2 low cross-resistance with standard agents clearly adds to the
potential of P2 being a clinically useful anti-tumour agent. WNhat
Log lC5 P2 then is the mechanism for increased toxicity- of P2 against primary
cultures and other non-proliferating cell systems? Although. the
Correlation between log IC5 values for Mel and P2 in 49 primary druc appears to act mechanistically similar to Mel both in the cell
mour samples. R = Pearson's correlation coefficient lines and the primarv cultures. one may speculate on. at least. t o
possible explanations. On one hand the effect of a bifunctional
alkvlating agent is related to the frequency of DNA damage such
GSH lexels for P2 than Mel sensitivity. The explanation as DNA cross-links (Lew-ensohn et al. 1991a). The frequency of
lack of GSH-mediated resistance in reponse to P2 does not DNA cross-links may. hoxxever. be regulated by- DNA repair
to involhe intracellular liberation of m-L-SL as this mechanisms. xhich at least in some cell lines is correlated with
nd shows RFs of similar magnitude to Mel for GSH-asso- drug sensitivity (Batist et al. 1989). It would then seem possible
resistance. Altered substrate recognition of m-L-SL that a bifunctional aly lating agent in the form of an oligopeptide
ptides bx cellular GSH-dependent enzymes is one potential would not be recognized and excised from the DNA by the same
tion for the phenomenon. In xitro sensitivity to Mel has repair mechanism as Mel. On the other hand another possible
sly been noted to result in only a limited increase in toxi- explanation is that of a more effectixe cellular uptake of the
rted by PTC as compared xx-ith Mel in freshly obtained bifunctional alkyvlator xxhen in the form of an oligopeptide as
arrox- myeloma cells from untreated patients. compared xx-ith Mel only. In this context. it is interestinc to note
stinglv. this findine xxas contrasted by the relatixvelv that another tripeptide of m-L-SL. 3-(p-fluorophenx1)-L-alany 1-3-
iced sensitixity to PTC in cell populations xxith in xitro [m-bis(2-chloroethxl) aminopheny l]-L-alany-l-L-methionine ethyl
ce to Mel (Lewxensohn et al. 199lb). When comparing Mel. ester]. PTT.119. has shown increased anti-tumour activitv (Yagi et
PTC and P2 on freshly obtained myeloma cells. P2 al. 1984. 1988) and the delivery of this peptide into tumour cells
d the highest actixity ( data not shown). x-as found to be significantl1 greater than Mel. It x-as subsequently
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found that this peptide used multiple transport pathways in L1210
cells (Yagi et al. 1988). Both the above alternatives are currently
being explored.
In whole blood P2 is rapidly degraded to m-L-SL. afact that may
limit the activity of the drug in vivo (Ehrsson et al, 1993). This
finding indicates that peptidase activity probably degrades the P2
compound intracellularly. Degradation ofdi-, tni- and tetrapeptides
has previously been observed in erythrocytes and leucocytes that
have high peptidase activity (Stem et al, 1951). More attempts will
be made to characterize exactly the intracellular degradation of P2
and test its efficacy in comparison with m-L-SL in vivo.
In the present study, we used a human cell line panel in combi-
nation with a panel ofprimary tumour cultures from patients for in
vitro evaluation of differential drug responses of PTC oligopep-
tides. In a previous study (Dhar et al. 1996) we showed that the
present cell line panel is capable of detecting mechanisms of
action ofstandard drugs in addition to its ability to evaluate sensi-
tivity to drugs to defined types of mechanisms of resistance.
Complementary to this, non-clonogenic assays used on fresh
primary tumour cultures from patients have been shown to mimic
the known clinical activity pattern ofstandard drugs. We have also
previously shown that non-clonogenic cytotoxicity assays such as
the FMCA can detect tumour type specific activity retrospectively
for a series of standard drugs (Nygren et al. 1994) and prospec-
tively for early phase I-H drugs such as vinorelbine. idarubicin.
CdA. gemcitabine. taxol and topotecan (Larsson et al. 1994:
Larsson and Nygren, 1994; Csoka et al. 1995: Nygren et al. 1995:
Fridborg et al. 1996: Jonsson et al, 1997). Thus, experience gained
so far suggests that these model systems may be valid tools for
initial predictions ofthe activity and potential utility ofnovel anti-
cancer drugs.
In summary, we have demonstrated high anti-tumour activity of
a m-L-SL oligopeptide against cell lines and primary cultures of
tumour cells from patients. The drug appears to show retained
activity against non-proliferating cell systems, shows a positive
therapeutic index and demonstrates low levels ofcross-resistance
with standard drugs. Formal testing of these in vitro predictions
will require in vivo testing in relevant tumour models and these
studies are currently under way.
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